{
  "dataset": "Plainly Graded peptide status",
  "status_as_of": "2026-10-17",
  "disclaimer": "Based on public sources; we cannot guarantee it is correct. Not medical advice. A doctor should prescribe and confirm.",
  "disclaimer_url": "https://plainlygraded.com/disclaimer/",
  "rows": [
    {
      "slug": "bpc-157",
      "name": "BPC-157",
      "aliases": "body protection compound; PL 14736; wolverine (with TB-500)",
      "fda_status": "not_approved",
      "fda_detail": "Not FDA-approved for any use",
      "compounding_status": "under_review",
      "compounding_detail": "Not on the 503A bulks list. FDA advisers recommended it on July 23, 2026; the vote is non-binding and no rule has been proposed",
      "wada_status": "prohibited",
      "wada_section": "S0",
      "wada_detail": "Prohibited at all times under the 2026 WADA List (S0, non-approved substances)",
      "overall_grade": "C",
      "last_change": "2026-07-23",
      "source_check": "pending",
      "status_as_of": "2026-10-17",
      "url": "https://plainlygraded.com/peptides/bpc-157/"
    },
    {
      "slug": "epitalon",
      "name": "Epitalon",
      "aliases": "",
      "fda_status": "not_approved",
      "fda_detail": "Not FDA-approved for any use",
      "compounding_status": "under_review",
      "compounding_detail": "Not on the 503A bulks list. FDA advisers recommended it on July 24, 2026; the vote is non-binding and no rule has been proposed",
      "wada_status": "not_named",
      "wada_section": "",
      "wada_detail": "Not named on the 2026 WADA List. Because it is unapproved, the catch-all S0 section may still apply; ask USADA before use",
      "overall_grade": "",
      "last_change": "2026-07-24",
      "source_check": "pending",
      "status_as_of": "2026-10-17",
      "url": "https://plainlygraded.com/peptides/epitalon/"
    },
    {
      "slug": "ghk-cu",
      "name": "GHK-Cu",
      "aliases": "copper peptide; GHK copper",
      "fda_status": "cosmetic_only",
      "fda_detail": "Legal as a cosmetic ingredient; not FDA-approved as a drug",
      "compounding_status": "not_eligible",
      "compounding_detail": "Injectable form off Category 2 since April 15, 2026 but not eligible for compounding; FDA advisers are due to review it before the end of February 2027",
      "wada_status": "not_named",
      "wada_section": "",
      "wada_detail": "Not named on the 2026 WADA List. Because it is unapproved, the catch-all S0 section may still apply; ask USADA before use",
      "overall_grade": "C",
      "last_change": "2026-04-15",
      "source_check": "pending",
      "status_as_of": "2026-10-17",
      "url": "https://plainlygraded.com/peptides/ghk-cu/"
    },
    {
      "slug": "kpv",
      "name": "KPV",
      "aliases": "lysine-proline-valine; alpha-MSH fragment",
      "fda_status": "not_approved",
      "fda_detail": "Not FDA-approved for any use",
      "compounding_status": "under_review",
      "compounding_detail": "Not on the 503A bulks list. FDA advisers recommended it on July 23, 2026; the vote is non-binding and no rule has been proposed",
      "wada_status": "not_named",
      "wada_section": "",
      "wada_detail": "Not named on the 2026 WADA List. Because it is unapproved, the catch-all S0 section may still apply; ask USADA before use",
      "overall_grade": "D",
      "last_change": "2026-07-23",
      "source_check": "pending",
      "status_as_of": "2026-10-17",
      "url": "https://plainlygraded.com/peptides/kpv/"
    },
    {
      "slug": "mots-c",
      "name": "MOTS-c",
      "aliases": "",
      "fda_status": "not_approved",
      "fda_detail": "Not FDA-approved for any use",
      "compounding_status": "under_review",
      "compounding_detail": "Not on the 503A bulks list. FDA advisers recommended it on July 23, 2026; the vote is non-binding and no rule has been proposed",
      "wada_status": "not_named",
      "wada_section": "",
      "wada_detail": "Not named on the 2026 WADA List. Because it is unapproved, the catch-all S0 section may still apply; ask USADA before use",
      "overall_grade": "",
      "last_change": "2026-07-23",
      "source_check": "pending",
      "status_as_of": "2026-10-17",
      "url": "https://plainlygraded.com/peptides/mots-c/"
    },
    {
      "slug": "pt-141",
      "name": "PT-141",
      "aliases": "bremelanotide; Vyleesi",
      "fda_status": "approved_narrow",
      "fda_detail": "Approved as Vyleesi for hypoactive sexual desire disorder in premenopausal women only",
      "compounding_status": "not_applicable",
      "compounding_detail": "Available as an approved, labelled product for its approved use",
      "wada_status": "unverified",
      "wada_section": "",
      "wada_detail": "WADA status not yet checked against the List",
      "overall_grade": "Approved",
      "last_change": "",
      "source_check": "pending",
      "status_as_of": "2026-10-17",
      "url": "https://plainlygraded.com/peptides/pt-141/"
    },
    {
      "slug": "retatrutide",
      "name": "Retatrutide",
      "aliases": "reta; GLP-3; LY3437943",
      "fda_status": "investigational",
      "fda_detail": "Not FDA-approved and not yet filed; Lilly says it plans to submit in early 2027",
      "compounding_status": "not_applicable",
      "compounding_detail": "An unapproved drug in trials; there is no lawful compounded version",
      "wada_status": "not_named",
      "wada_section": "",
      "wada_detail": "GLP-1 agonists are not prohibited, but retatrutide is unapproved, so section S0 may apply until approval; ask USADA",
      "overall_grade": "A",
      "last_change": "2026-09-29",
      "source_check": "pending",
      "status_as_of": "2026-10-17",
      "url": "https://plainlygraded.com/peptides/retatrutide/"
    },
    {
      "slug": "semax",
      "name": "Semax",
      "aliases": "",
      "fda_status": "not_approved",
      "fda_detail": "Not FDA-approved for any use",
      "compounding_status": "under_review",
      "compounding_detail": "Not on the 503A bulks list. FDA advisers recommended it on July 24, 2026; the vote is non-binding and no rule has been proposed",
      "wada_status": "not_named",
      "wada_section": "",
      "wada_detail": "Not named on the 2026 WADA List. Because it is unapproved, the catch-all S0 section may still apply; ask USADA before use",
      "overall_grade": "",
      "last_change": "2026-07-24",
      "source_check": "pending",
      "status_as_of": "2026-10-17",
      "url": "https://plainlygraded.com/peptides/semax/"
    },
    {
      "slug": "sermorelin",
      "name": "Sermorelin",
      "aliases": "Geref; GRF 1-29",
      "fda_status": "formerly_approved",
      "fda_detail": "Previously approved as Geref; discontinued",
      "compounding_status": "unverified",
      "compounding_detail": "Compounding status not yet checked against FDA's current lists",
      "wada_status": "prohibited",
      "wada_section": "S2",
      "wada_detail": "Prohibited at all times under the 2026 WADA List (S2.2.4, growth hormone releasing factors)",
      "overall_grade": "",
      "last_change": "",
      "source_check": "pending",
      "status_as_of": "2026-10-17",
      "url": "https://plainlygraded.com/peptides/sermorelin/"
    },
    {
      "slug": "ss-31",
      "name": "SS-31",
      "aliases": "elamipretide; Forzinity",
      "fda_status": "approved_narrow",
      "fda_detail": "Reported approved as Forzinity for Barth syndrome only (being verified)",
      "compounding_status": "not_applicable",
      "compounding_detail": "Available as an approved product for its approved use",
      "wada_status": "not_named",
      "wada_section": "",
      "wada_detail": "Not named on the 2026 WADA List; ask USADA before use",
      "overall_grade": "Approved",
      "last_change": "",
      "source_check": "pending",
      "status_as_of": "2026-10-17",
      "url": "https://plainlygraded.com/peptides/ss-31/"
    },
    {
      "slug": "tb-500",
      "name": "TB-500",
      "aliases": "thymosin beta-4 fragment; Wolverine (with BPC-157)",
      "fda_status": "not_approved",
      "fda_detail": "Not FDA-approved for any use",
      "compounding_status": "under_review",
      "compounding_detail": "Not on the 503A bulks list. FDA advisers recommended it on July 23, 2026; the vote is non-binding and no rule has been proposed",
      "wada_status": "prohibited",
      "wada_section": "S2",
      "wada_detail": "Prohibited at all times under the 2026 WADA List (S2.3: thymosin beta-4 and its derivatives, e.g. TB-500)",
      "overall_grade": "D",
      "last_change": "2026-07-23",
      "source_check": "pending",
      "status_as_of": "2026-10-17",
      "url": "https://plainlygraded.com/peptides/tb-500/"
    },
    {
      "slug": "tesamorelin",
      "name": "Tesamorelin",
      "aliases": "Egrifta",
      "fda_status": "approved_narrow",
      "fda_detail": "Approved as Egrifta for excess abdominal fat in HIV-associated lipodystrophy only",
      "compounding_status": "not_applicable",
      "compounding_detail": "Available as an approved, labelled product for its approved use",
      "wada_status": "prohibited",
      "wada_section": "S2",
      "wada_detail": "Prohibited at all times under the 2026 WADA List (S2.2.4, growth hormone releasing factors)",
      "overall_grade": "Approved",
      "last_change": "",
      "source_check": "pending",
      "status_as_of": "2026-10-17",
      "url": "https://plainlygraded.com/peptides/tesamorelin/"
    },
    {
      "slug": "tirzepatide",
      "name": "Tirzepatide",
      "aliases": "Mounjaro; Zepbound; tirz",
      "fda_status": "approved",
      "fda_detail": "Approved as Mounjaro (type 2 diabetes) and Zepbound (chronic weight management)",
      "compounding_status": "not_applicable",
      "compounding_detail": "Available as an approved, labelled product",
      "wada_status": "not_prohibited",
      "wada_section": "",
      "wada_detail": "GLP-1 agonists are not prohibited; WADA says the status is unchanged for 2027",
      "overall_grade": "Approved",
      "last_change": "",
      "source_check": "pending",
      "status_as_of": "2026-10-17",
      "url": "https://plainlygraded.com/peptides/tirzepatide/"
    }
  ]
}